I previously posted that ABI-H0731 appeared to have only modest efficacy (#msg-156515976), which is why ASMB has a backup CpAM compound for HBV called ABI-H2158. Today’s failure presumably spells the end of ABI-H0731 as a serious candidate.
Note: ENTA has an HBV CpAM in phase-2 that the CEO says is much more potent than ABI-H0731 (#msg-156787041).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.